Scientific Reference
Retatrutide + Cagrilintide
Evidence profile: Component evidence only — this formulation has not itself been studied
This combination pairs a triple incretin agonist with an amylin analogue, representing one of the most advanced multi-pathway metabolic research protocols currently explored.\n\nRetatrutide targets GLP-1, GIP, and glucagon pathways, while Cagrilintide acts on amylin receptors. No clinical trials have evaluated this specific combination, and all effects remain theoretical.
Published Research
REDEFINE 1
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
Garvey WT et al. · The New England journal of medicine · 2025 · Clinical · Evidence for Cagrilintide
PMID 40544433 — View on PubMedTriple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
Jastreboff AM et al. · The New England journal of medicine · 2023 · Clinical · Evidence for Retatrutide
PMID 37366315 — View on PubMedOnce-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
Lau DCW et al. · Lancet (London, England) · 2021 · Clinical · Evidence for Cagrilintide
PMID 34798060 — View on PubMedEfficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial
Bajaj HS et al. · Lancet (London, England) · 2026 · Clinical · Evidence for Retatrutide
PMID 42250575 — View on PubMedEfficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial
Yamauchi T et al. · The lancet. Diabetes & endocrinology · 2026 · Clinical · Evidence for Cagrilintide
PMID 42009015 — View on PubMedCagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
Rosenstock J et al. · Lancet (London, England) · 2026 · Clinical · Evidence for Cagrilintide
PMID 42251856 — View on PubMed